Nintedanib Eg (Eurogenerics) (Nintedanib)

The drug blocks several receptor tyrosine kinases—VEGFR, PDGFR and FGFR—thereby reducing fibroblast activation, angiogenesis and the deposition of extracellular matrix. This inhibition curtails the fibrotic remodeling process that characterises progressive lung scarring.

The specific dose and dosing schedule are determined by the prescribing physician based on the patient’s condition, weight, organ function and concomitant therapies. Clinicians follow approved labeling and may adjust the regimen according to tolerability and clinical response.

Safety data for Nintedanib during pregnancy and lactation are limited. The drug should be used only if the potential benefit justifies the potential risk to the fetus or infant, and women of child‑bearing potential are generally advised to use effective contraception.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any temperature‑controlled requirements) and the necessary import documentation.

The principal alternative antifibrotic agent is pirfenidone, which also slows lung function decline in idiopathic pulmonary fibrosis. Nintedanib targets a broader range of tyrosine kinases, while pirfenidone’s mechanism involves inhibition of transforming growth factor‑β signaling. Choice between them depends on efficacy, tolerability, drug‑interaction profile and individual patient factors.

Nintedanib should be stored at ambient temperature, preferably below 25 °C, in its original container to protect it from moisture and light. Keep the product out of reach of children and avoid exposing it to extreme temperatures or humidity.

The medication is taken orally, usually with food to lessen gastrointestinal discomfort. Tablets are swallowed whole with a full glass of water and should be taken at the same times each day as directed by the healthcare provider.

Patients should be alert for signs of liver injury (elevated liver enzymes, jaundice), severe bleeding, and gastrointestinal perforation. Prompt medical evaluation is advised if symptoms such as unexplained abdominal pain, black stools, or yellowing of the skin or eyes occur.

Nintedanib is contraindicated in individuals with known hypersensitivity to the drug or any of its excipients, and in patients with severe hepatic impairment. Caution is also warranted for those with active bleeding disorders or uncontrolled cardiovascular disease.